Fig. 6From: Targeting integrated stress response with ISRIB combined with imatinib treatment attenuates RAS/RAF/MAPK and STAT5 signaling and eradicates chronic myeloid leukemia cellsScheme of the mechanisms targeted by imatinib and ISRIB combinationBack to article page